Clinical trial
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
NCT00080080 · Point Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00080080 |
|---|---|
| Title | Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer |
| Official title | Phase 2 Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Point Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | talabostat (PT-100) tablets, Docetaxel |
| First posted | Mar 24, 2004 |
| Last update posted | Jun 8, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: